Gerold Bepler

发表

Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.

Eric B Haura, Bhupendra Rawal, Michael J Schell, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer.

Nithya Ramnath, S. Wiseman, G. Bepler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-small cell lung cancer: Clinical practice guidelines in oncology

Quynh-Thu Le, Renato Martins, Joe Y. Chang, 2006 .

Proteomic Contributions to Personalized Cancer Care*

Timothy J. Yeatman, John M. Koomen, Rebecca Sutphen, 2008, Molecular & Cellular Proteomics.

Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income.

Colleen M McBride, Santanu Datta, Greg Samsa, 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Choline phosphate cytidylyltransferase‐α is a novel antigen detected by the anti‐ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomas

Wei Chen, Brian L Hood, Thomas P Conrads, 2014, Cancer.

RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer.

Alan Cantor, George Simon, G. Bepler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis.

Zhong Zheng, Elisabeth Brambilla, Michael J Schell, 2011, The American journal of pathology.

Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer.

Alan Cantor, Zhong Zheng, Eric B Haura, 2005, Chest.

Phase 2 trial of docetaxel and gefitinib in the first‐line treatment of patients with advanced nonsmall‐cell lung cancer (NSCLC) who are 70 years of age or older

Eric B Haura, Michael J Schell, Rachna Kapoor, 2008, Cancer.

Molecular classification of nonsmall cell lung cancer using a 4‐protein quantitative assay

Taxiarchis Botsis, David L Rimm, Dimitrios Dougenis, 2012, Cancer.

Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer Cells

Valsamo Anagnostou, Robert Camp, G. Bepler, 2012, PloS one.

DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.

Zhong Zheng, Tingan Chen, G. Bepler, 2007, The New England journal of medicine.

Lung cancer. Practice organization.

G. Bepler, J. Ruckdeschel, John C Ruckdeschel, 2003, Chest.

Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach

Zhong Zheng, Yun Yen, Chandan Guha, 2016, Pancreas.

Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.

Alan Cantor, Frank Walsh, George Simon, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Glucocorticoid Receptor Status Is a Principal Determinant of Variability in the Sensitivity of Non–Small-Cell Lung Cancer Cells to Pemetrexed

G. Bepler, A. Shields, S. Gadgeel, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006.

Iztok Hozo, Benjamin Djulbegovic, G. Bepler, 2008, Archives of internal medicine.